SCHEMBL17458649

SCHEMBL17458649

CC=Cc1c(F)cccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.56
MAT2A P31153 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.50
HPGD P15428 6/20 0.50
LMNA P02545 2/20 0.50
ALOX12 P18054 1/20 0.50
ATM Q13315 1/20 0.50
MAPT P10636 3/20 0.49
KMT2A Q03164 3/20 0.49
MDM4 O15151 1/20 0.49
MDM2 Q00987 1/20 0.49
RAB9A P51151 8/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 2/20 0.46
TDP1 Q9NUW8 2/20 0.44
POLB P06746 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16067619 1.00 KCNH2 (0.56) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL5412758 0.87 KCNH2 (0.50) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL3434659 0.84 KMT2A (0.50) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL6805365 0.84 KMT2A (0.50) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL12186097 0.84 NFE2L2 (0.54) KCNH2MAT2ALMNAMAPTRAB9A
SCHEMBL15050564 0.84 NFE2L2 (0.54) KCNH2MAT2ALMNAMAPTRAB9A
SCHEMBL14416464 0.79 KCNH2 (0.51) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL9967742 0.79 KCNH2 (0.51) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL257070 0.79 KCNH2 (0.51) KCNH2MAT2ASMN1; SMN2HPGDLMNA
SCHEMBL19055317 0.79 KCNH2 (0.51) KCNH2MAT2ASMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
CN-111419830-B Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes 比皮艾思药物研发有限公司 2024-01-30 CN disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
CN-115996905-A Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases 生物药品解决方案有限公司 2023-04-21 CN disclosed
CN-109071424-B Sulfamate derivative compound, preparation method and application thereof 生物药品解决方案有限公司 2022-01-14 CN disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
CN-111419830-A Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epilepsy-related syndromes 比皮艾思药物研发有限公司 2020-07-17 CN disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
EP-3423433-A1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES Bio-Pharm Solutions Co., Ltd. (KR) 2019-01-09 EP disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses STS, SULT2A1, SULT1A1 KCNH2 2186/4885MAT2A 1116/4885SMN1; SMN2 54/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT KCNH2 3553/4885MAT2A 2385/4885SMN1; SMN2 629/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 KCNH2 227/4885MAT2A 343/4885SMN1; SMN2 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.